Dog leukocyte antigen-haploidentical stem cell allografts after anti-CD44 therapy and nonmyeloablative conditioning in a preclinical canine model

Transplantation

Volumn 82, Issue 3, 2006, Pages 332-339

  Fukuda, Takahiro ^a   Kerbauy, Fabio R ^a   Gooley, Theodore ^a,b   Santos, Erlinda B ^a   Storb, Rainer ^a,b   Sandmaier, Brenda M ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Anti CD44 mAb; Haploidentical transplantation; Nonmyeloablative transplantation

Indexed keywords

CD14 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN; HERMES ANTIGEN; LEUKOCYTE ANTIGEN; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD44; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL COUNT; CHIMERA; DOG; DOSE RESPONSE; GRAFT REJECTION; HAPLOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; IMMUNOTHERAPY; LYMPHOCYTE TRANSFER; NONHUMAN; NONMYELOABLATIVE CONDITIONING; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; T LYMPHOCYTE SUBPOPULATION; WHOLE BODY RADIATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD44; CELL COUNT; CHIMERA; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; GRAFT REJECTION; GRAFT VS HOST DISEASE; HAPLOIDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LEUKOCYTES; MODELS, ANIMAL; MYELOID CELLS; STEM CELLS; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 33747108478     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000228908.10775.b0     Document Type: Article

References (39)

1. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048.
2. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390.
3. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003; 102: 2021.
4. Storb R, Deeg HJ. Failure of allogeneic canine marrow grafts after total body irradiation: Allogeneic "resistance" vs transfusion induced sensitization. Transplantation 1986; 42: 571.
5. Raff RF, Sandmaier BM, Graham T, et al. "Resistance" to DLA-nonidentical canine unrelated marrow grafts is unrestricted by the major histocompatibility complex. Exp Hematol 1994; 22: 893.
6. Schuening F, Storb R, Goehle S, et al. Facilitation of engraftment of DLA-nonidentical marrow by treatment of recipients with monoclonal antibody directed against marrow cells surviving radiation. Transplantation 1987; 44: 607.
7. Sandmaier BM, Storb R, Appelbaum FR, Gallatin WM. An antibody that facilitates hematopoietic engraftment recognizes CD44. Blood 1990; 76: 630.
8. Sandmaier BM, Storb R, Bennett KL, et al. Epitope specificity of CD44 for monoclonal antibody dependent facilitation of marrow engraftment in a canine model. Blood 1998; 91: 3494.
9. Sandmaier BM, Fukuda T, Gooley T, et al. Dog leukocyte antigenhaploidentical stem cell allografts after anti-CD44 therapy and reduced-intensity conditioning in a preclinical canine model. Exp Hematol 2003; 31: 168.
10. Wagner JL, Burnett RC, Works JD, Storb R. Molecular analysis of DLA-DRBB1 polymorphism. Tissue Antigens 1996; 48: 554.
11. Wagner JL, Burnett RC, DeRose SA, et al. Histocompatibility testing of dog families with highly polymorphic microsatellite markers. Transplantation 1996; 62: 876.
12. Burnett RC, Francisco LV, DeRose SA, et al. Identification and characterization of a highly polymorphic microsatellite marker within the canine MHC class I region. Mamm Genome 1995; 6: 684.
13. Wagner JL, Works JD, Storb R. DLA-DRB1 and DLA-DQB1 histocompatibility typing by PCR-SSCP and sequencing (Brief Communication). Tissue Antigens 1998; 52: 397.
14. Raff RF, Deeg HJ, Farewell VT, et al. The canine major histocompatibility complex. Population study of DLA-D alleles using a panel of homozygous typing cells. Tissue Antigens 1983; 21: 360.
15. Storb R, Raff RF, Graham T, et al. Marrow toxicity of fractionated versus single dose total body irradiation is identical in a canine model. Int J Radiat Oncol Biol Phys 1993; 26: 275.
16. Zaucha JM, Zellmer E, Georges G, et al. G-CSF-mobilized peripheral blood mononuclear cells added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required. Biol Blood Marrow Transplant 2001; 7: 613.
17. Sandmaier BM, Storb R, Santos EB, et al. Allogeneic transplants of canine peripheral blood stem cells mobilized by recombinant canine hematopoietic growth factors. Blood 1996; 87: 3508.
18. Lee R, Storb R, Little M-T, et al. Percutaneous central dual-lumen catheter for apheresis in the canine. J Invest Surg 2002; 15: 337.
19. Deeg HJ, Storb R. Canine marrow transplantation models. Curr Topics Vet Res 1994; 1: 103.
20. Ladiges WC, Storb R, Thomas ED. Canine models of bone marrow transplantation. Lab Anim Sci 1990; 40: 11.
21. n polymorphisms to determine the origin of blood cells after allogeneic canine marrow grafting. Transplantation 1994; 58: 701.
22. Raff RF, Deeg HJ, Loughran TP, Jr., et al. Characterization of host cells involved in resistance to marrow grafts in dogs transplanted from unrelated DLA-nonidentical donors. Blood 1986; 68: 861.
23. Storb R, Weiden PL, Graham TC, et al. Hemopoietic grafts between DLA-identical canine littermates following dimethyl myleran. Evidence for resistance to grafts not associated with DLA and abrogated by antithymocyte serum. Transplantation 1977; 24: 349.
24. Tan PH, Sandmaier BM, Stayton PS. Characterization of an anti-CD44 single-chain FV antibody that stimulates natural killer cell activity and induces TNFa release. Immunol Invest 1995; 24: 907.
25. Tan PH, Liu Y, Santos EB, Sandmaier BM. Mechanisms of enhancement of natural killer activity by an antibody to CD44: Increase in conjugate formation and release of tumor necrosis factor a. Cell Immunol 1995; 164: 255.
26. Tan PHS, Santos EB, Rossbach HC, Sandmaier BM. Enhancement of natural killer activity by an antibody to CD44. J Immunol 1993; 150: 812.
27. Kolb HJ, Gunther W, Schumm M, et al. Adoptive immunotherapy in canine chimeras. Transplantation 1997; 63: 430.
28. Georges GE, Storb R, Thompson JD, et al. Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation. Blood 2000; 95: 3262.
29. Lewalle P, Delforge A, Aoun M, et al. Growth factors and DLI in adult haploidentical transplant: a three-step pilot study towards patient and disease status adjusted management. Blood Cells Molecules Dis 2004; 33: 256.
30. Pelot MR, Pearson DA, Swenson K, et al. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biol Blood Marrow Transplant 1999; 5: 133.
31. Panse JP, Bastianelli C, Santos EB, et al. Dog leukocyte antigen nonidentical unrelated canine marrow grafts: enhancement of engraftment by both CD4 and CD8 T cells. Transplantation 2003; 76: 474.
32. Reisner Y, Gur H, Reich-Zeliger S, et al. Crossing the HLA barriers (Review). Blood Cells Molecules Dis 2004; 33: 206.
33. Bethge WA, Hegenbart U, Stuart MJ, et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 2004; 103: 790.
34. Dey BR, McAfee S, Colby C, et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2003; 9: 320.
35. Baron F, Baker JE, Storb R, et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004; 104: 2254.
36. Mielcarek M, Martin P, Torok-Storb B. Suppression of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood mononuclear cells. Blood 1997; 89: 1629.
37. Aranha FJ, Vigorito AC, de Sousa CA, et al. The influence of the graft monocytes in the outcome of allogeneic bone marrow transplantation. Haematologica 2002; 87: 219.
38. + cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia 2005; 19: 822.
39. Martin PJ. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans. J Exp Med 1993; 178: 703.